BeOne Medicines to Invest $300 Million to Expand US Drug Manufacturing
MT Newswires Live
Jul 23
BeOne Medicines (ONC) said Thursday it plans to invest $300 million to expand its flagship clinical and commercial-stage manufacturing and research and development center at the Princeton West Innovation Campus in Hopewell, New Jersey.
The expansion will advance BeOne's oncology pipeline of more than 35 clinical and commercial-stage assets, the company said.
The investment will fund the construction of a new three-story, 145,000-square-foot building near BeOne's existing Hopewell facilities, increasing the total campus footprint to about 545,000 square feet, the company added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.